ONCAlert | 2017 NANETS Symposium

The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer

Mothaffar F. Rimawi, MD
Published Online: 5:23 PM, Wed December 6, 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.